BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) issued its earnings results on Wednesday. The company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.39), Zacks reports.
BriaCell Therapeutics Trading Down 0.3 %
NASDAQ BCTX traded down $0.01 on Wednesday, hitting $3.65. 26,695 shares of the company traded hands, compared to its average volume of 191,580. The business’s 50 day moving average price is $5.10 and its 200-day moving average price is $9.28. BriaCell Therapeutics has a 52-week low of $3.00 and a 52-week high of $45.60. The company has a market capitalization of $13.54 million, a price-to-earnings ratio of -0.27 and a beta of 1.71.
Analysts Set New Price Targets
Separately, HC Wainwright lifted their target price on shares of BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- Insider Trades May Not Tell You What You Think
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
